Related Experiment Video
Updated: Apr 18, 2026
Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
Published on: October 12, 2017
Correlation between elevated Lp(a) levels and cardiovascular risk in coronary heart disease patients with different
Tao Sun1, Wenhao Zhang2, Pingyan Fei1
1Department of Cardiology, Songjiang Hospital, Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, 201600, P.R. China.
Insights
Elevated lipoprotein(a) (Lp(a)) significantly increases cardiovascular risk, especially when homocysteine (HCY) levels are also high. This combined risk is not observed with low HCY, highlighting the importance of assessing both markers.
Area of Science:
- Cardiology
- Biochemistry
- Clinical Research
Background:
- Lipoprotein(a) (Lp(a)) is an established independent risk factor for cardiovascular disease.
- Homocysteine (HCY) may modulate the association between Lp(a) and recurrent cardiovascular events.
Purpose of the Study:
- To investigate the relationship between Lp(a) levels and recurrent cardiovascular events in patients with coronary heart disease.
- To analyze how varying homocysteine (HCY) concentrations influence this association.
Main Methods:
- A 36-month follow-up study of 530 coronary heart disease patients.
- Patients were stratified into low and high Lp(a) groups.
- Kaplan-Meier curves and Cox proportional hazards models were used to analyze major adverse cardiovascular events (MACE) and acute coronary events (ACE) in relation to Lp(a) and HCY levels.
Main Results:
- Elevated Lp(a) was a significant risk factor for MACE and ACE overall.
- In patients with moderate-to-high HCY, elevated Lp(a) significantly increased MACE and ACE risk.
- No significant association between elevated Lp(a) and MACE or ACE was found in patients with low HCY levels.
Conclusions:
- Elevated Lp(a) amplifies the risk of recurrent cardiovascular events in the presence of high HCY.
- The association between Lp(a) and cardiovascular risk is dependent on HCY concentration.
- Combined assessment of Lp(a) and HCY is recommended for targeted interventions to reduce residual cardiovascular risk.
Background:
In recent years, the impact of lipoprotein(a) (Lp(a)) on the prognosis of coronary heart disease has been increasingly recognized. Lp(a) is an independent risk factor for cardiovascular disease, and studies have shown that homocysteine (HCY) may influence the association between Lp(a) and the risk of recurrent cardiovascular events. This study investigates the association between Lp(a) levels and recurrent cardiovascular events in patients with varying HCY concentrations.
Methods:
We conducted a 36-month follow-up on 530 patients with coronary heart disease and divided them into low-Lp(a) and high-Lp(a) groups based on Lp(a) levels. The incidence rates of major adverse cardiovascular events (MACE) and acute coronary events (ACE) were compared between the two groups. The association between elevated Lp(a) and cardiovascular risk in different subgroups(based on HCY concentration) was analyzed using Kaplan-Meier curves and Cox proportional hazards models.
Results:
Elevated Lp(a) remained a significant risk factor for both MACE (HR = 2.07, 95% CI = 1.37-3.12, P = 0.001) and ACE (HR = 2.83, 95% CI = 1.67-4.81, P = 0.001) overall. In subgroup analyses, elevated Lp(a) in patients with moderate-to-high HCY levels constituted a high-risk cohort for MACE and ACE occurrence (HR = 1.87, 95% CI = 1.01-3.46, P = 0.046;HR = 2.85, 95% CI = 1.32-6.18, P = 0.008). Among those with low HCY levels, elevated Lp(a) showed no association with either MACE or ACE (P > 0.05).
Conclusion:
When HCY is elevated, patients with increased Lp(a) experience amplified risk of recurrent cardiovascular events. This association shifts when HCY is at low levels. Future efforts should emphasize combined assessment of Lp(a) and HCY and explore targeted intervention strategies to reduce residual cardiovascular risk.
Related Concept Videos
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
01:26Atherosclerosis III: Management
01:26Coronary Artery Disease IV: Preventive Measures
01:30Coronary Artery Disease I: Introduction
01:25Blood Studies for Cardiovascular System III: Serum Lipid Profile
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
01:27Atherosclerosis II: Clinical Manifestations and Diagnostic Tests